A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension
Latest Information Update: 16 Jul 2024
At a glance
- Drugs BOS-580 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Boston Pharmaceuticals
- 03 Jul 2024 Planned number of patients changed from 180 to 205.
- 05 Jun 2024 According to a Boston Pharmaceutical media release, data will be presented at the European Association for the Study of the Liver (EASL) Congress 2024, held from June 5-8 in Milan, Italy.
- 20 May 2024 Status changed from recruiting to active, no longer recruiting.